|
We ask that you make clear who designed the study, who gathered the data, who analyzed the data, who vouches for the data and the analysis, and who wrote the paper (see editorial in the September 13, 2001 issue). The Methods section should include a brief statement about this. In the event of publication, the information in your disclosure forms will be posted to the website with your article (with any dollar amounts redacted). If your Journal submission is accepted for publication and subsequently selected for the CME program, the Accreditation Council for Continuing Medical Education (AACME) requires that financial disclosure (stating any author's relevant financial relationships or attestation of no relevant financial relationships) appear with the article in print. We will ask the corresponding author to draft a disclosure statement based on the information in the submitted disclosure forms. The statement should describe the authors’ relationships with companies that make products relevant to the paper. The statement should specify the type of relationships (e.g., consulting, paid speaking, grant support, equity, patents) EACH author has with EACH company.
DISCLOSURE FOOTNOTE SAMPLE
Dr. Johnson reports having served as a consultant to Bayer. Dr. Williams reports having been paid lecture fees by AstraZeneca, Merck, and TAP. Drs. Allen, Jones, and Williams report having received grant support from Merck. Dr. Lewis reports having equity interests in Pfizer and Merck. A U.S. patent entitled “Methods of Assessing Transplant Rejection” (6125876) was issued on January 10. 2002; Dr. McCarthy is one of the inventors. The patent is owned jointly by Harvard and Massachusetts General Hospital. A patent on the use of canalept (CNA4XMP) for the treatment of this condition has been assigned to Pfizer and the University of Illinois; neither Dr. Ames nor Dr. Hamilton has a financial interest in the patent. Dr. Ames and Dr. Hamilton are consultants to Pfizer, as well as to other companies that manufacture treatments for this condition. Drs. Roberts and Jenkins have assigned to Biotech Pharmaceuticals their inventions made as employees of the company and have received no royalties from Biotech for these inventions. Dr. Roberts receives royalties for inventions he made before becoming an employee of Biotech. Dr. Simon reports having served as an expert witness in tobacco litigation during the past five years. Dr. Levy reports having received consulting fees from Unilever, Wyeth, and Monsanto and having received a grant and holding stock options and related patents with Panacea. Dr. Elton, who was an employee of GIBCO while the study was being carried out, is currently a consultant to GIBCO and has stock options in Genentech. Dr. Sullivan and Dr. Smith are employees of GIBCO. Dr. Fuller reports having served on the advisory boards of Wyeth–Ayerst, Pfizer, and Otsuka. Dr. Hastings reports having been a member of speakers’ bureaus sponsored by Bristol-Myers Squibb and Parke-Davis and is a stockholder or has other ownership interest in Pfizer and Eli Lilly.
For further information regarding manuscripts, please see the instructions on submitting your manuscript and editorial policies of the Journal.
|
